Rapport Therapeutics, Inc. 4

CEO Abraham Ceesay of Rapport Therapeutics, Inc. sold 51,499 shares of common stock for about $2.4 million on August 10–11, 2026 under a Rule 10b5-1 plan.

On August 10–11, 2026, Rapport Therapeutics, Inc. Chief Executive Officer Abraham Ceesay sold a total of 51,499 shares of the company’s common stock in multiple open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2026, at weighted average prices between approximately $45.97 and $48.62 per share. The sales, which totaled roughly $2.4 million in gross proceeds, reduced his direct holdings from 523,436 shares to 486,108 shares, while he also continues to have indirect beneficial ownership of 81,729 shares through the Ceesay Family Irrevocable Trust and 20,729 shares through the Dorothy Ceesay Irrevocable Trust. The footnotes note that each reported price is a weighted average for trades executed over price ranges on the respective dates, and the reporting person undertakes to provide detailed breakdowns upon request.

Filing Facts

CIK

2012593

Ticker

RAPP

Form

4

Source Type

fda

Accession

0001193125-26-346995

Alert Tier

7